Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, open label study of durvalumab (medi4736) in combination with stereotactic body radiotherapy (sbrt) in androgen-intact patients with oligo metastatic prostate cancer measuring psa response

Next Previous
X
Search
Trial Profile

A phase II, open label study of durvalumab (medi4736) in combination with stereotactic body radiotherapy (sbrt) in androgen-intact patients with oligo metastatic prostate cancer measuring psa response

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAPRI
  • Sponsors AstraZeneca

    • Most Recent Events

    • 15 Feb 2020 Trial design presented at the 2020 Genitourinary Cancers Symposium
    • 10 May 2019 Status changed from not yet recruiting to recruiting.
    • 26 Mar 2019 According to Australian New Zealand Clinical Trials Registry, the anticipated date for last participant enrollment 12/20/2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top